TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18279523

Group type: EXPERIMENTAL
Intervention: Aquamin (2400 mg/d)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (1500 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Combined treatment (Glucosamine sulfate 1500 mg/d + Aquamin 2400 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 16536135

Group type: EXPERIMENTAL
Intervention: Intoxicated participants with lower WRAT3 scores
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intoxicated participants
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Participants with lower cognitive reserve (WRAT3 scores)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Participants' perception of high- and low-risk partners
Number of subjects: 120
Study: 14518597

Group type: EXPERIMENTAL
Intervention: Diclofenac-K 12.5 mg
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 10863250

Group type: EXPERIMENTAL
Intervention: Behavioral-graded activity program based on operant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care in physiotherapy (pain-contingent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral-graded activity program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care in physiotherapy
Number of subjects: 0
Study: 7974348

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metoprolol CR
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2493869

Group type: EXPERIMENTAL
Intervention: Moderate dietary sodium restriction for three months (n = 17)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sodium supplementation (Slow Sodium 80 mmol daily) for one month
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo for one month
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual diabetic diet (control group)
Number of subjects: 34
Study: 30668274

Group type: EXPERIMENTAL
Intervention: Anodal rTPJ HD-tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 28526798

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26468853

Group type: EXPERIMENTAL
Intervention: Peritonsillar levobupivacaine hydrochloride and dexamethasone infiltration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Peritonsillar saline infiltration (Control Group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 23328319

Group type: EXPERIMENTAL
Intervention: Alternating-frequency TENS (4 Hz for 3 s/110 Hz for 3 s) at low intensity (strong but comfortable)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Alternating-frequency TENS (4 Hz for 3 s/110 Hz for 3 s) at high intensity (strong and uncomfortable but not painful)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (no TENS)
Number of subjects: 208
Study: 21308825

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with an extract from Phaseolus vulgaris and Cynara scolymus for 2 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 19122550

Group type: EXPERIMENTAL
Intervention: Landiolol (bolus injection of 0.031 mg.kg(‐1) and continuous infusion at a rate of 0.01 mg.kg(‐1).min(‐1))
Number of subjects: 25

Group type: COMPARATOR
Intervention: Physiological saline (Control Group B)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Landiolol (Group A)
Number of subjects: 25
Study: 17322413

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15447905

Group type: EXPERIMENTAL
Intervention: Dual-fortified salt (DFS) with 25 microg I/g salt and 2 mg Fe/g salt
Number of subjects: 158

Group type: COMPARATOR
Intervention: Iodized salt
Number of subjects: 158
Study: 11464036

Group type: EXPERIMENTAL
Intervention: Transurethral vaporesection (TUVRP)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard transurethral resection (TURP)
Number of subjects: 185
Study: 9541184

Group type: EXPERIMENTAL
Intervention: Modified Nottingham Prognostic Index with ER and PgR
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: Modified Nottingham Prognostic Index without ER and PgR
Number of subjects: 1629

Group type: COMPARATOR
Intervention: Danish index
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: High risk patients with positive hormone receptors
Number of subjects: 1629
Study: 8772223

Group type: EXPERIMENTAL
Intervention: Synthetic pentasaccharide (SR 90107/ORG 31540) administered subcutaneously at doses of 4000, 8000, or 12,000 anti-Xa units (6, 12, or 18 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic pentasaccharide (SR 90107/ORG 31540) at 12,000 anti-Xa units
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fraxiparine at 13,000 IU
Number of subjects: 0
Study: 1699443

Group type: EXPERIMENTAL
Intervention: HS-HES solution (72 g/l NaCl, 60 g/l HES, 2400 mosmol/l)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 6% HES solution (200/0.5)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HS-HES
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 6% HES
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HES
Number of subjects: 90
Study: 6110218

Group type: EXPERIMENTAL
Intervention: Flutroline (CP-36,584)
Number of subjects: 0
Study: 31311521

Group type: EXPERIMENTAL
Intervention: Community health worker deployment
Number of subjects: 380000
Study: 28685497

Group type: EXPERIMENTAL
Intervention: 2-sample method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Differences in posttests
Number of subjects: 0
Study: 25330866

Group type: EXPERIMENTAL
Intervention: Men-only group workshops
Number of subjects: 283

Group type: COMPARATOR
Intervention: Health partner group workshops
Number of subjects: 283
Study: 23979731

Group type: EXPERIMENTAL
Intervention: AIGIV (3.5 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AIGIV (7.1 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AIGIV (14.2 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AIGIV administered 12 h postexposure
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AIGIV administered 24 h postexposure
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AIGIV in trigger-based intervention studies
Number of subjects: 90
Study: 21829969

Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanic acid (ACG)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Oxacillin plus ceftriaxone (OCG)
Number of subjects: 104
Study: 19481656

Group type: EXPERIMENTAL
Intervention: Ropeway method (ILTR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional method (C group)
Number of subjects: 34
Study: 17284637

Group type: COMPARATOR
Intervention: EP01572 (0.005, 0.05, 0.5 mg/kg body weight)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: EP01572 (0.125 and 0.25 mg/kg body weight)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ID administration of EP01572 (0.2 mg/kg body weight)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ID perfusion of EP01572 (0.35 mg/kg body weight)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ID perfusion of EP01572 (0.5 mg/kg body weight)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 36
Study: 15123848

Group type: EXPERIMENTAL
Intervention: Increased dose of fluoxetine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Lithium or desipramine augmentation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 101
Study: 11310719

Group type: EXPERIMENTAL
Intervention: Oseltamivir 2 mg/kg twice daily
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oseltamivir 30, 45 and 60mg oral suspension recommended twice daily based on weight
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg capsule
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 9415368

Group type: EXPERIMENTAL
Intervention: Subjects instructed to hold fixation on the cross and ignore the disparity modulation of the noise pattern
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjects instructed to follow the movement of the noise pattern as accurately as possible
Number of subjects: 0
Study: 8116721

Group type: EXPERIMENTAL
Intervention: Computer-controlled pulsatile infusion
Number of subjects: 358

Group type: COMPARATOR
Intervention: Aggressively managed continuous infusion
Number of subjects: 358

Group type: COMPARATOR
Intervention: Conservatively managed continuous infusion
Number of subjects: 358
Study: 3054197

Group type: EXPERIMENTAL
Intervention: 1 mcg/kg of Bpr combined with local anesthetic (group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mcg/kg of Bpr combined with local anesthetic (group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Local anesthetic only (group A)
Number of subjects: 30
Study: 30459099

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU/every 2 weeks) plus Probiotic (8 × 10^9 CFU/day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Probiotic (8 × 10^9 CFU/day)
Number of subjects: 87
Study: 28796075

Group type: EXPERIMENTAL
Intervention: Muscle gap approach under a minimally invasive channel technique
Number of subjects: 68

Group type: COMPARATOR
Intervention: Median approach
Number of subjects: 68
Study: 26599332

Group type: EXPERIMENTAL
Intervention: HspB5 (7.5, 12.5, or 17.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24077070

Group type: EXPERIMENTAL
Intervention: Group-based anger-management intervention
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fidelity ratings
Number of subjects: 27
Study: 21182345

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r 600 mg/100 mg twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control protease inhibitor (PI)-based HAART
Number of subjects: 0
Study: 18245961

Group type: EXPERIMENTAL
Intervention: Ultrasound phacoemulsification (group 1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fluid-based system (group 2)
Number of subjects: 42
Study: 16389204

Group type: EXPERIMENTAL
Intervention: Interim methadone maintenance
Number of subjects: 319

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 319
Study: 12535809

Group type: EXPERIMENTAL
Intervention: Tezosentan (50 mg/h)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tezosentan (100 mg/h)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 10781482

Group type: EXPERIMENTAL
Intervention: Inhaling 66% N(2)O in O(2) (Group FN)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo with 66% N(2)O in O(2) (Group PN)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Inhaling 100% O(2) (Group FO)
Number of subjects: 117
Study: 8923551

Group type: COMPARATOR
Intervention: Surround stationary
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surround motion increased
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surround motion same or opposite direction
Number of subjects: 0
Study: 1395985

Group type: EXPERIMENTAL
Intervention: Two-piece Conseal system (Group A)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: One-piece Conseal system (Group B)
Number of subjects: 57
Study: 3937970

Group type: EXPERIMENTAL
Intervention: Therapy A (vincristine/ifosfamide/tegafur)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Therapy B (fluorouracil/trofosfamide/methotrexate/melphalan)
Number of subjects: 109
Study: 30915778

Group type: EXPERIMENTAL
Intervention: Diet only (Group 1, n = 21)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Diet + myo-inositol (MI) 4 g + folic acid 400 µg daily (Group 2, n = 10)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Diet + MI 1.1 g + D-chiro-inositol (DCI) 27.6 mg + folic acid 400 µg daily (Group 3, n = 13)
Number of subjects: 43
Study: 29913017

Group type: EXPERIMENTAL
Intervention: PRX002 (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, 10 mg/kg, 30 mg/kg, or 60 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26265098

Group type: EXPERIMENTAL
Intervention: Ivabradine 2.5 mg administered every 12 hours for 4.5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg administered every 12 hours for 4.5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivabradine 10 mg administered every 12 hours for 4.5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine data analysis
Number of subjects: 0
Study: 25277543

Group type: EXPERIMENTAL
Intervention: Point-of-Care C-reactive protein test and/or brief intervention with safety net advice
Number of subjects: 2560

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 2560
Study: 22193780

Group type: EXPERIMENTAL
Intervention: Resistance + impact exercise program
Number of subjects: 106

Group type: COMPARATOR
Intervention: Stretching placebo program
Number of subjects: 106
Study: 19129262

Group type: EXPERIMENTAL
Intervention: Behaviour modification intervention
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study: 17187965

Group type: EXPERIMENTAL
Intervention: 400 mg modafinil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15166843

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation strategies (low tidal volumes, PEEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surfactant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 0
Study: 11782664

Group type: EXPERIMENTAL
Intervention: Artistic gymnasts
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Rhythmic gymnasts
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Gymnasts (artistic and rhythmic)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 17
Study: 10621863

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined results
Number of subjects: 35
Study: 7865087

Group type: EXPERIMENTAL
Intervention: Group I - oral hygiene training program based on self-diagnosis and the 'linking method'; 20 minutes sessions at two-day intervals for the first three visits, followed by monthly check-ups for 4 months and then every 3 months for reevaluation.
Number of subjects: 222

Group type: COMPARATOR
Intervention: Group II - detailed oral hygiene instruction on cleaning every tooth surface using dental tape, toothbrush, and fluoride dentifrice; same recall intervals as Group I.
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control Group III - no specific intervention mentioned; standard care.
Number of subjects: 222
Study: 2659293

Group type: EXPERIMENTAL
Intervention: Aztreonam 1 g/day intramuscularly
Number of subjects: 186

Group type: COMPARATOR
Intervention: Gentamicin 80 mg i.m. twice daily
Number of subjects: 186
Study: 30192329

Group type: EXPERIMENTAL
Intervention: Intraperitoneal local anesthetic (ropivacaine 100 mg bolus pre- and post-dissection, 20 mg/h continuous infusion for 48 hours)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (normal saline equivalent)
Number of subjects: 86
Study: 27435972

Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg/day
Number of subjects: 1331

Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg/day
Number of subjects: 1331
Study: 24683916

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 222

Group type: COMPARATOR
Intervention: Delayed group (Control)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 222
Study: 23884802

Group type: EXPERIMENTAL
Intervention: Porous tantalum cementless tibial component (Group 1)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Cemented conventional tibial component (Group 2)
Number of subjects: 145
Study: 20845225

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for schizophrenia, duration 12 weeks, assessed through 15-min semistructured interviews and APES ratings.
Number of subjects: 0
Study: 18362865

Group type: EXPERIMENTAL
Intervention: UC781 gel 0.1%, 0.25%, 1.0%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (0%)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: UC781 gel 1%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: UC781 gel (all concentrations)
Number of subjects: 48
Study: 16980315

Group type: EXPERIMENTAL
Intervention: Acupuncture (n = 160)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care (n = 81)
Number of subjects: 241
Study: 12684358

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 60) received detailed advice on achieving a weight reduction of 10% or more through a low‐energy Mediterranean‐style diet and increased physical activity.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (n = 60) was given general information about healthy food choices and exercise.
Number of subjects: 120
Study: 11079860

Group type: EXPERIMENTAL
Intervention: PTEVAL computerized home-based physical therapy intervention
Number of subjects: 0
Study: 9240868

Group type: EXPERIMENTAL
Intervention: Caesarean section performed prior to labour
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine vaginal delivery
Number of subjects: 0
Study: 1524994

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with monitoring of white blood cell counts (WBC) and absolute neutrophil counts (ANC)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with monitoring of WBC and ANC
Number of subjects: 52
Study: 3888726

Group type: EXPERIMENTAL
Intervention: 20 mg ibuprofen/kg body-weight
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 30 mg ibuprofen/kg body-weight
Number of subjects: 44
Study: 31587925

Group type: EXPERIMENTAL
Intervention: Blood TNF expression and serum TNF‐α levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA)
Number of subjects: 0
Study: 29509769

Group type: EXPERIMENTAL
Intervention: Information framed as a gain
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Information framed as a loss
Number of subjects: 722

Group type: COMPARATOR
Intervention: Control group (no information)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Information intervention (pooled groups)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Information framed as a loss vs. information framed as a gain
Number of subjects: 722
Study: 27497037

Group type: EXPERIMENTAL
Intervention: Fused, colorized diffusion weighted imaging (DWI) and anatomic T2 images
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine contrast-enhanced T1 images
Number of subjects: 20
Study: 25217858

Group type: EXPERIMENTAL
Intervention: Icare PRO
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Tono‐Pen
Number of subjects: 47
Study: 23118244

Group type: EXPERIMENTAL
Intervention: Sleep education pamphlet
Number of subjects: 36

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 36
Study: 20472299

Group type: EXPERIMENTAL
Intervention: Escitalopram (up to 20mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18593651

Group type: EXPERIMENTAL
Intervention: Single vital-capacity breathing with 7.2% inspiratory sevoflurane in 6 L/min oxygen followed by assisted ventilation with 3.5% sevoflurane for 4.5 minutes.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 µg/kg pretreatment before induction.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Assisted ventilation with 3.5% sevoflurane for 4.5 minutes.
Number of subjects: 36
Study: 16442890

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) combined with optimal medical treatment
Number of subjects: 500

Group type: COMPARATOR
Intervention: Optimal medical treatment alone
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: CRT
Number of subjects: 500
Study: 14617231

Group type: EXPERIMENTAL
Intervention: Twice daily BIAsp30
Number of subjects: 403

Group type: COMPARATOR
Intervention: Twice daily NPH insulin
Number of subjects: 403
Study: 11855033

Group type: EXPERIMENTAL
Intervention: Participation in the health focused study abroad program
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (did not participate in the tour)
Number of subjects: 17
Study: 8837118

Group type: EXPERIMENTAL
Intervention: Post-mastectomy radiotherapy with adjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obsolete radiotherapy techniques
Number of subjects: 0
Study: 1364937

Group type: EXPERIMENTAL
Intervention: Enteric-coated naproxen tablets (ECT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Plain naproxen tablets (PT)
Number of subjects: 39
Study: 3989392

Group type: EXPERIMENTAL
Intervention: Diet with a polyunsaturated to saturated fat (P/S) ratio of 0.9 (group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diet with a polyunsaturated to saturated fat (P/S) ratio of 0.4 (group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 40
Study: 31464476

Group type: EXPERIMENTAL
Intervention: Oral exogenous progesterone (200 mg twice per day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31504118

Group type: EXPERIMENTAL
Intervention: Trilaciclib
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Trilaciclib + E/P
Number of subjects: 122
Study: 28747330

Group type: EXPERIMENTAL
Intervention: Whey protein load of 30 g (120 kcal)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Whey protein load of 70 g (280 kcal)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Flavored water control drink (0 kcal)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Whey protein (both doses)
Number of subjects: 16
Study: 25709076

Group type: EXPERIMENTAL
Intervention: Electronic prompt
Number of subjects: 437

Group type: COMPARATOR
Intervention: Control (no electronic prompt)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Meta-analysis of all studies
Number of subjects: 437